載入...
Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
Recent phase II and III studies with intravenous immunoglobulin (IVIG) in patients with Alzheimer’s disease (AD) did not find evidence for the slowing of AD progression compared to placebo-treated patients, in contrast to encouraging results in pilot studies. An additional phase III trial is ongoing...
Na minha lista:
| 發表在: | J Neuroinflammation |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265363/ https://ncbi.nlm.nih.gov/pubmed/25476011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12974-014-0198-z |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|